DOCSLIB.ORG

Avoiding the Pitfalls When Quantifying Thyroid Hormones and Their Metabolites Using Mass Spectrometric Methods: the Role of Quality Assurance

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Avoiding the Pitfalls When Quantifying Thyroid Hormones and Their Metabolites Using Mass Spectrometric Methods: the Role of Quality Assurance Molecular and Cellular Endocrinology xxx (2017) 1e13 Contents lists available at ScienceDirect Molecular and Cellular Endocrinology journal homepage: www.elsevier.com/locate/mce Avoiding the pitfalls when quantifying thyroid hormones and their metabolites using mass spectrometric methods: The role of quality assurance * Keith Richards, Eddy Rijntjes, Daniel Rathmann, Josef Kohrle€ Institut für Experimentelle Endokrinologie, Charite-Universitatsmedizin€ Berlin, Berlin, Germany article info abstract Article history: This short review aims to assess the application of basic quality assurance (QA) principles in published Received 18 November 2016 thyroid hormone bioanalytical methods using mass spectrometry (MS). The use of tandem MS, in Received in revised form particular linked to liquid chromatography has become an essential bioanalytical tool for the thyroid 20 January 2017 hormone research community. Although basic research laboratories do not usually work within the Accepted 20 January 2017 constraints of a quality management system and regulated environment, all of the reviewed publications, Available online xxx to a lesser or greater extent, document the application of QA principles to the MS methods described. After a brief description of the history of MS in thyroid hormone analysis, the article reviews the Keywords: Thyroid hormone metabolites application of QA to published bioanalytical methods from the perspective of selectivity, accuracy, Tandem mass spectrometry precision, recovery, instrument calibration, matrix effects, sensitivity and sample stability. During the last 3-Iodothyronamine decade the emphasis has shifted from developing methods for the determination of L-thyroxine (T4) and 0 Iodothyronine 3,3 ,5-triiodo-L-thyronine (T3), present in blood serum/plasma in the 1e100 nM concentration range, to metabolites such as 3-iodo-L-thyronamine (3-T1AM), 3,5-diiodo-L-thyronine (3,5-T2) and 3,3’-diiodo-L- 0 thyronine (3,3 -T2). These metabolites seem likely to be present in the low pM concentrations; conse- quently, QA parameters such as selectivity and sensitivity become more critical. The authors conclude that improvements, particularly in the areas of analyte selectivity, matrix effect measurement/docu- mentation and analyte recovery would be beneficial. © 2017 Elsevier B.V. All rights reserved. Contents 1. Scope of the review . ................................................. 00 2. Background . ................................................. 00 3. The history of mass spectrometry in thyroid hormone analysis . ..................... 00 4. Quality assurance and method validation . .................................... 00 4.1. Selectivity . ....................... 00 4.2. Accuracy, precision and recovery . ....................... 00 4.3. Instrument calibration . ....................... 00 4.4. Matrix effects and the use of ISTD . ....................... 00 4.5. Sensitivity . ....................... 00 4.6. Stability . ....................... 00 0 Abbreviations: CLIA, Chemiluminescence immunoassays; 3,5-T2, 3,5-Diiodo-L-thyronine; 3,3 -T2, 3,3‘-Diiodo-L-thyronine; ELISA, Enzyme-linked immunosorbent assay; FDA, Food and Drug Administration; GC-MS, Gas chromatography-mass spectrometry; IA, Immunoassay; 3-T1AM, 3-Iodothyronamine; ID, Isotope dilution; LC, Liquid chromatography; LC-MS, Liquid chromatography mass spectrometry; LC-MS/MS, Liquid chromatography tandem mass spectrometry; LLOD, Lower limit of detection; LLOQ, Lower limit of quantification; m/z, Mass/charge ratio; MS, Mass spectrometry; QA, Quality assurance; TH, Thyroid hormones; THM, Thyroid hormones and metabolites; T4,L- 0 0 3 Thyroxine, 3,3’,5,5 -Tetraiodo-L-thyronine; T3, 3,3 ,5-Triiodo-L-thyronine; SRM, Selected reaction monitoring; MRM, Multiple reaction monitoring; MS , Triple MS; ISTD, À À Internal standard; SPE, Solid phase extraction; nM, nanomolar (nmolL 1); pM, picomolar (pmolL 1). * Corresponding author. Charite-Universit atsmedizin€ Berlin, Institut für Experimentelle Endokrinologie, Augustenburger Platz 1, 13353 Berlin, Germany. E-mail address: [email protected] (J. Kohrle).€ http://dx.doi.org/10.1016/j.mce.2017.01.032 0303-7207/© 2017 Elsevier B.V. All rights reserved. Please cite this article in press as: Richards, K., et al., Avoiding the pitfalls when quantifying thyroid hormones and their metabolites using mass spectrometric methods: The role of quality assurance, Molecular and Cellular Endocrinology (2017), http://dx.doi.org/10.1016/j.mce.2017.01.032 2 K. Richards et al. / Molecular and Cellular Endocrinology xxx (2017) 1e13 4.7. Equilibration . .................................................. 00 5. Immunoassays . ..................... 00 6. Summary .................................................................................................... ..................... 00 Funding...................................................................................................... ..................... 00 Conflict of interest statement . ..................... 00 Acknowledgements . .................................................. 00 References . .................................................. 00 1. Scope of the review review are equally applicable to all biological matrices. The use of mass spectrometry (MS) for the analysis of thyroid 2. Background hormones. (TH) and TH metabolites (THM) in biological samples has THM are a group of low molecular mass iodine-containing become widespread. MS methods for the determination of TH and hormonally active compounds derived from the amino acid L- THM in human (Siekmann, 1987; Thienpont et al., 1994; De tyrosine. The pro-hormone L-thyroxine (T4, Fig. 1A), the more Brabandere et al., 1998; Tai et al., 2002, 2004; Thienpont et al., 0 biologically active 3,3 ,5-Triiodo-L-thyronine (T3, Fig. 1B) and the 1999; Van Uytfanghe et al., 2004; Soukhova et al., 2004; Gu et al., 0 di-iodometabolites 3,5-T2 and 3,3 -T2 (Fig. 1D and E respectively) 2007; Yue et al., 2008; Saba et al., 2010; DeBarber et al., 2008; belong to the thyronine family of compounds. The de-carboxylated, Galli et al., 2012; Jonklaas et al., 2014; Kunisue et al., 2011a; de-iodinated derivatives of T4, include 3-iodothyronamine (3- Wang and Stapleton, 2010; Kahric-Janicic et al., 2007; Ackermans T1AM, Fig. 1C); these are known as thyronamines. et al., 2010) and animal (Saba et al., 2010; DeBarber et al., 2008; Endogenous TH are found in tissues, blood and other body fluids Kunisue et al., 2011a; Wang and Stapleton, 2010; Ackermans and their accurate measurement in these biological matrices is a et al., 2010; Hackenmueller and Scanlan, 2012; Nagao et al., 2011; key requirement for both clinical diagnostic and research purposes. Kunisue et al., 2011b; Kiebooms et al., 2014; Hansen et al., 2016) TH and THM may exist in both free and protein-bound forms in blood serum/plasma, animal tissues (Saba et al., 2010; Ackermans biological matrices and it is desirable to have available bioanalytical et al., 2010, 2012; Kunisue et al., 2011c; Kunisue et al., 2010), cell methods to determine both free and total (i.e. free plus bound) culture lysates (Saba et al., 2010; Piehl et al., 2008) and superna- concentrations in both blood and tissues. Among low molecular tants (Rathmann et al., 2015), saliva (Higashi et al., 2011), and urine mass hormones the avid and extremely high affinity binding of TH (Aqai et al., 2012; Fan et al., 2013) have been published. Over the and THM to several binding proteins in the blood and various last 25 years the availability of affordable, high sensitivity benchtop subcellular compartments is a unique challenge to every diagnostic tandem mass spectrometers, in particular those coupled to liquid approach intending their quantification (Refetoff, 2000; Roy et al., chromatography (LC-MS/MS) and as a consequence of the manu- 2012; Little, 2016). facturer's constant search for new markets and hence new appli- cations, the thyroid research community has access to this additional powerful tool to compliment traditional immunoassay 3. The history of mass spectrometry in thyroid hormone (IA)-based methods. The move of LC-MS/MS into new application analysis areas brings with it not only a new bioanalytical approach and gains in productivity, but also potential pitfalls. These pitfalls are perhaps T4 and T3 are 99.97 and 99.7% respectively bound to carrier more familiar to the early adopters of the technique, who tended to proteins in the circulation (Spencer, 2000). The availability of TH to be active in application areas subject to quality management sys- cells is considered to be dependent on their free rather than tems and accredited/regulated environments. The need for quality protein-bound concentrations (Cheng et al., 2010), making the assurance (QA), including method validation has been recognised concentrations of free T3 and T4 of major diagnostic interest to and taken on board by the majority of TH research groups pub- clinicians. Hence, free T4 and T3 concentrations are clinically lishing bioanalytical MS methods; however, the implementation of important parameters that are routinely measured on a high QA and the interpretation of data is variable. The limited availability throughput daily basis in blood samples from adult patients. The of certified reference materials and isotopically labelled internal accurate, precise determination of total versus free T4 and T3 in standard (ISTD) compounds and the lack of proficiency testing are blood serum present quite different challenges related to their particular limitations.
Load more

Recommended publications
  • An Online Solid-Phase Extraction–Liquid Chromatography–Tandem
    327 An online solid-phase extraction–liquid chromatography–tandem mass spectrometry method to study the presence of thyronamines in plasma 13 and tissue and their putative conversion from C6-thyroxine M T Ackermans1, L P Klieverik2, P Ringeling3, E Endert1, A Kalsbeek2,4 and E Fliers2 1Laboratory of Endocrinology, F2-131.1., Department of Clinical Chemistry and 2Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands 3Spark Holland, P. de Keyserstraat 8, 7825 VE, Emmen, The Netherlands 4Netherlands Institute for Neuroscience, Meibergdreef 47, 1105 BA, Amsterdam, The Netherlands (Correspondence should be addressed to M T Ackermans; Email: [email protected]) Abstract 13 Thyronamines are exciting new players at the crossroads of or brain samples of rats treated with C6-T4. Surprisingly, thyroidology and metabolism. Here, we report the develop- our method did not detect any endogenous T1AM or T0AM ment of a method to measure 3-iodothyronamine (T1AM) in plasma from vehicle-treated rats, nor in human plasma or and thyronamine (T0AM) in plasma and tissue samples. thyroid tissue. Although we are cautious to draw general The detection limit of the method was 0.25 nmol/l in plasma conclusions from these negative findings and in spite of the and 0.30 pmol/g in tissue both for T1AM and for T0AM. fact that insufficient sensitivity of the method related to Using this method, we were able to demonstrate T1AM and extractability and stability of T0AM cannot be completely T0AM in plasma and liver from rats treated with synthetic excluded at this point, our findings raise questions on the thyronamines.
    [Show full text]
  • And Thyroxine Analogs in the Near UV (Specifically Labeled Iodothyronines/HPLC) BEN VAN DER WALT* and HANS J
    Proc. NatL Acad. Sci. USA Vol. 79, pp. 1492-1496, March 1982 Biochemistry Synthesis of thyroid hormone metabolites by photolysis of thyroxine and thyroxine analogs in the near UV (specifically labeled iodothyronines/HPLC) BEN VAN DER WALT* AND HANS J. CAHNMANN National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20205 Communicated by Bernhard Witkop, December 10, 1981 ABSTRACT Photolysis ofthyroxine and its analogs in the near thoroughly mixed and then centrifuged. To 100 Al ofthe clear UV permitted synthesis in good yield of picogram to gram quan- supernatant (pH 7.5) was added carrier-free Na 25I (==50 uCi; tities of thyroid hormone metabolites. Preparation of the same 1 Ci = 3.7 X 1010 becquerels) and then 10 ,ul of a freshly pre- metabolites by classical chemical synthesis requires multistep pro- pared aqueous solution ofchloramine T (4 mg/ml). The reaction cedures. Specifically labeled metabolites of high specific activity was stopped after 2 min by addition of 10 ,ul of sodium meta- (e.g., those carrying the label in the nonphenolic ring) were ob- bisulfite (a 1:10 dilution of a saturated aqueous solution). The tained by photolysis ofappropriately labeled thyroxine or 3,3',5'- reaction mixture was fractionated by HPLC as described below triiodothyronine (reverse triiodothyronine). Some ofthese labeled for the ofirradiated solutions. The combined 3,5-diio- metabolites, which are required for metabolic studies (3-iodothy- analysis ronine and 3,3'-diiodothyronine, labeled in the nonphenolic ring), dotyrosine-containing fractions were desalted (3) and then evap- had not previously been obtained by other methods.
    [Show full text]
  • 210632Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 210632Orig1s000 NON-CLINICAL REVIEW(S) NDA 210632 Reviewer: Arulasanam. K. Thilagar DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH PHARMACOLOGY/TOXICOLOGY NDA/BLA REVIEW AND EVALUATION Application number: NDA 210632 Supporting document/s: SDN1, SN0001 Applicant’s letter date: 06/15/2018 CDER stamp date: 06/15/2018 Product: Levothyroxine Sodium Injection Indication: For treatment of myxedema coma Applicant: Fresenius Kabi USA, Three Corporate Drive, Lake Zurich, IL, USA Review Division: Division of Metabolism and Endocrine Products Reviewer: Arulasanam K. Thilagar, PhD Supervisor/Team Leader: C. Lee Elmore, PhD Division Director: Lisa Yanoff, MD (Acting) Project Manager: Linda V. Galgay, RN, MSN Disclaimer Except as specifically identified, all data and information discussed below and necessary for approval of NDA 210632 are owned by Fresenius Kabi USA or are data for which Fresenius Kabi USA has obtained a written right of reference. Any information or data necessary for approval of NDA 21632 that Fresenius Kabi USA does not own or have a written right to reference constitutes one of the following: (1) published literature, or (2) a prior FDA finding of safety or effectiveness for a listed drug, as reflected in the drug’s approved labeling. Any data or information described or referenced below from reviews or publicly available summaries of a previously approved application is for descriptive purposes
    [Show full text]
  • The Peripheral Conversion of Thyroxine (T4) Into Triiodothyronine
    The Peripheral Conversion of Thyroxine (T4) into i • Triiodothyronine (T3) and Reverse triiodothyronine (rT3) 3 The Peripheral Conversion of Thyroxine (T4) into Triiodothyronine (T3) sts- a», and Reverse triiodothyronine (rT3) ACADEMISCH PROEFSCHRIFT ter verkrijging van de graad van doctor in de Geneeskunde aan de Universiteit van Amsterdam, ?••!• op gezag van de Rector Magnificus dr. J.Bruyn, hoogleraar in de Faculteit der Letteren, in het openbaar te verdedigen in de aula der Universiteit (tijdelijk in de Lutherse Kerk, ingang Singel 411, hoek Spui), op donderdag 15 november 1979 om 16.00 uur precies door WILLEM MAARTEN WIERSINGA geboren te Leiden AMSTERDAM 1979 I; Promoter : Dr. J.L. Touber g Coreferent : Prof. dr. A. Querido 'l Copromotor : Prof. dr. M. Koster Dit proefschrift is bewerkt op de afdeling endocrinologie (Dr. J.L. Touber) van de kliniek voor inwendige ziekten (Prof.Dr. M. Koster en Prof.Dr. J. Vreeken) van het Wilhelmina Gasthuis, Academisch Ziekenhuis bij de Universiteit van Amsterdam. Het verschijnen van dit proefschrift werd mede mogeiijk gemaakt door steun van de Nederlandse Hartstichting en van ICI Holland B.V. I i*' Ii: VOORWOORD I Dit proefschrift is niet opgedragen aan iemand in het bijzonder, daar het tv, verrichte onderzoek in eerste instantie mijn eigen nieuwsgierigheid heeft 1} bevredigd en ik de indruk heb dat het meer mijn eigen genoegen heeft r ' gediend dan dat van anderen. Een woord van dank aan de velen die in de : afgelopen jaren bijgedragen hebben tot deze studies, is wel op zijn plaats, '. daar het onderzoek zonder hun steun niet mogelijk zou zijn geweest, en ; vooral ook omdat ik met plezier terugdenk aan de onderlinge , samenwerking.
    [Show full text]
  • Metabolism of 3-Iodotyrosine and 3,5-Diiodotyrosine by Thyroid Extracts
    Scholars' Mine Masters Theses Student Theses and Dissertations 1970 Metabolism of 3-iodotyrosine and 3,5-diiodotyrosine by thyroid extracts Shih-ying Sun Follow this and additional works at: https://scholarsmine.mst.edu/masters_theses Part of the Chemistry Commons Department: Recommended Citation Sun, Shih-ying, "Metabolism of 3-iodotyrosine and 3,5-diiodotyrosine by thyroid extracts" (1970). Masters Theses. 7056. https://scholarsmine.mst.edu/masters_theses/7056 This thesis is brought to you by Scholars' Mine, a service of the Missouri S&T Library and Learning Resources. This work is protected by U. S. Copyright Law. Unauthorized use including reproduction for redistribution requires the permission of the copyright holder. For more information, please contact [email protected]. METABOLISM OF 3-IODOTYROSINE AND 3, 5-DIIODOTYROSINE BY THYROID EXTRACTS ..... ! ' BY SHm-YING SUN, 1943- A THESIS submitted to the faculty of UNIVERSITY OF MISSOURI - ROLLA in partial fulfillment of the requirements for the Degree of MASTER OF SCIENCE IN CHEMISTRY Rolla, Missouri 1970 T2328 c. I 73 pages Approved by i)n neiL (advisor) ~ .~et__ cf3v.~ /¢?£;;~ 183322 ii ABSTRACT A porcine thyroid enzyme was extracted from thyroid tissue by homo­ genization and differentia.! centrifugation. The enzyme was capable of metabol­ izing both 3-iodotyrosine and 3, 5-diiodotyrosine. All of the thyroid subcellular particles produced a fluorescent compound when incubated with these substrates. When the 1, 000 x g sediment was supplemented with the 48,000 x g supernatant a. second compound was formed. The compound was UV absorbing and has been identified as either 3-iodo-4-hydroxybenza.ldehyde or 3, 5-diiodo-4-hydroxy­ benzaldehyde depending upon which substrate was used.
    [Show full text]
  • UC San Francisco Electronic Theses and Dissertations
    UCSF UC San Francisco Electronic Theses and Dissertations Title Investigations of 3-iodothyronamine as a novel regulator of thyroid endocrinology Permalink https://escholarship.org/uc/item/2k21w7bm Author Ianculescu, Alexandra Georgiana Publication Date 2009 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California Investigations of 3-iodothyronamine as a novel regulator of thyroid endocrinology by Alexandra G. lanculescu DISSERTATION Submitted in partial satisfaction of the requirements for the degree of DOCTOR OF PHILOSOPHY In Biochemistry and Molecular Biology in the GRADUATE DIVISION of the UNIVERSITY OF CALIFORNIA, SAN FRANCISCO APProved4~ /~ ThomasScanlan .......r~ACT?-??:?.(d?.<;....· Kathleen Giacomini ........ ~ ..~ Robert Edwards Committee in Charge Deposited in the Library, University of California, San Francisco ............................................................................................................. Date University Librarian Degree Conferred: . Copyright 2009 by Alexandra G. Ianculescu ii Acknowledgements I would first like to thank my research advisors, Thomas Scanlan and Kathleen Giacomini, for guiding me through my graduate career. When I first heard Tom speak about thyronamines at a lunch seminar several years ago, I knew I had found an area of research that was sure to keep me interested and excited for not only my graduate work, but for a long time to come. Kathy, with her wide range of interests, generosity, and expertise in membrane transport, has provided invaluable help and support over the past couple of years. I am also grateful to the members of the Scanlan and Giacomini labs. They have been excellent sources of scientific advice and support, and I am lucky to have met several great friends there as well. I would also like to thank the UCSF Medical Scientist Training Program for financial support during my graduate studies.
    [Show full text]
  • Effects of the Thyroid Hormone Derivatives 3-Iodothyronamine and Thyronamine on Rat Liver Oxidative Capacity P
    Effects of the thyroid hormone derivatives 3-iodothyronamine and thyronamine on rat liver oxidative capacity P. Venditti, G. Napolitano, L. Di Stefano, G. Chiellini, R. Zucchi, T.S. Scanlan, S. Di Meo To cite this version: P. Venditti, G. Napolitano, L. Di Stefano, G. Chiellini, R. Zucchi, et al.. Effects of the thyroid hormone derivatives 3-iodothyronamine and thyronamine on rat liver oxidative capacity. Molecular and Cellular Endocrinology, Elsevier, 2011, 341 (1-2), pp.55. 10.1016/j.mce.2011.05.013. hal-00719874 HAL Id: hal-00719874 https://hal.archives-ouvertes.fr/hal-00719874 Submitted on 22 Jul 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Accepted Manuscript Effects of the thyroid hormone derivatives 3-iodothyronamine and thyronamine on rat liver oxidative capacity P. Venditti, G. Napolitano, L. Di Stefano, G. Chiellini, R. Zucchi, T.S. Scanlan, S. Di Meo PII: S0303-7207(11)00254-1 DOI: 10.1016/j.mce.2011.05.013 Reference: MCE 7845 To appear in: Molecular and Cellular Endocrinology Molecular and Cellular Endocrinology Received Date: 22 October 2010 Revised Date: 11 May 2011 Accepted Date: 11 May 2011 Please cite this article as: Venditti, P., Napolitano, G., Di Stefano, L., Chiellini, G., Zucchi, R., Scanlan, T.S., Di Meo, S., Effects of the thyroid hormone derivatives 3-iodothyronamine and thyronamine on rat liver oxidative capacity, Molecular and Cellular Endocrinology Molecular and Cellular Endocrinology (2011), doi: 10.1016/j.mce.
    [Show full text]